<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03188965</url>
  </required_header>
  <id_info>
    <org_study_id>18594</org_study_id>
    <secondary_id>2016-004484-39</secondary_id>
    <nct_id>NCT03188965</nct_id>
  </id_info>
  <brief_title>First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas</brief_title>
  <official_title>An Open-label, First-in-human, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose and / or Recommended Phase II Dose of the ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ATR(ataxia-telangiectasia and Rad3 related protein) inhibitor BAY1895344 is developed for&#xD;
      the treatment of patients with advanced solid tumors and lymphomas. The purpose of the&#xD;
      proposed trial is to evaluate the safety and tolerability of BAY1895344, and to identify the&#xD;
      maximum tolerated dose of BAY1895344 that could be safely given to cancer patients. Further,&#xD;
      the response of the cancer to the treatment will be determined.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 6, 2017</start_date>
  <completion_date type="Anticipated">February 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 18, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The maximum tolerated dose (MTD) and / or recommended Phase II dose (RP2D) of BAY1895344</measure>
    <time_frame>Up to 6 months, minimum: 1 cycle (= 21days)</time_frame>
    <description>Dose-escalation cohort during Part A. The MTD is defined as the maximum dose at which the incidence of dose-limiting toxicities (DLTs) during cycle 1 is below 30%, or the maximum dose tested, whichever is achieved first in the dose-escalation cohorts during Part A of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of DLTs during Cycle 1 in dose-escalation cohorts during Part A of the study</measure>
    <time_frame>During cycle 1, 1 cycle=21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of DLTs during Cycle 1 in dose-escalation cohorts during Part A.1 of the study</measure>
    <time_frame>During cycle 1, 1 cycle=28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of DLTs during Cycle 1 in dose-escalation cohorts during J-arm of the study</measure>
    <time_frame>During cycle 1, 1 cycle=21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidence of serious and nonserious treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Up to 30 days after end of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (area under the plasma concentration of BAY1895344 vs. time curve) from zero to 12 hours after single-dose (C1D1) and multiple-dose administrations (C1D10)</measure>
    <time_frame>At day 1 and day 10 of first cycle</time_frame>
    <description>In Part A, A.1, J-arm of Part A and Part B. Analysis of drug exposure and pharmacokinetic parameters in patients over a course of time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of BAY1895344 in cycle 1 after single-dose (C1D1) and multiple-dose administrations (C1D10)</measure>
    <time_frame>At day 1 and day 10 of first cycle</time_frame>
    <description>In Part A, A.1, J-arm of Part A and Part B. To support profiling pharmacokinetic of study drug in patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of patients with CR, PR, SD or PD (except for patients with castration resistant prostate cancer) consistent with the RECIST 1.1 criteria</measure>
    <time_frame>Through study completion, an average of 4 months</time_frame>
    <description>CR (complete response) PR (partial response) SD (stable disease) PD (progressive disease) RECIST (Response Evaluation Criteria in Solid Tumors)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of lymphoma patients with CR, PR, SD or PD consistent with the Lugano Classification</measure>
    <time_frame>Through study completion, an average of 4 months</time_frame>
    <description>CR (complete response) PR (partial response) SD (stable disease) PD (progressive disease)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of castration resistant prostate cancer patients with CR, PR, SD or PD consistent with the recommendations of the Prostate Cancer Working Group 3 (PCWG3)</measure>
    <time_frame>Through study completion, an average of 4 months</time_frame>
    <description>CR (complete response) PR (partial response) SD (stable disease) PD (progressive disease)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">241</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Dose escalation of BAY1895344 in Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-agent dose-escalation part. Part A has the objective to define the MTD and / or RP2D.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>J-arm of Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-agent dose-escalation part in Japanese patients. J-arm has the objective to confirm the MTD (or RP2D) dose is safe and tolerable in Japanese patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose expansion of BAY1895344 in Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-agent expansion part. Once the MTD has been defined, safety, PK profile, PD of target engagement, and preliminary efficacy will be further evaluated in Part B of the study. Once the MTD dose has been confirmed is safe and tolerable in Japanese patients, safety, PK profile, PD of target engagement, and preliminary efficacy will be further evaluated in Part B of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A.1: Single-agent dose escalation part</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A.1 - single-agent dose escalation part with alternative dosing schedule Patients with histologically confirmed solid tumors or NHL known to be positive for ATM loss and/or ATM deleterious mutations will be included.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1895344</intervention_name>
    <description>Study drug will be administered as scheduled.</description>
    <arm_group_label>Dose escalation of BAY1895344 in Part A</arm_group_label>
    <arm_group_label>Dose expansion of BAY1895344 in Part B</arm_group_label>
    <arm_group_label>J-arm of Part A</arm_group_label>
    <arm_group_label>Part A.1: Single-agent dose escalation part</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Part A - single-agent dose-escalation part:&#xD;
&#xD;
        - Patients with histologically confirmed solid tumors or non-Hodgkin's lymphoma (NHL).&#xD;
&#xD;
        J-arm of Part A - single-agent dose escalation in Japanese - Japanese patients with&#xD;
        histologically confirmed solid tumors. Patients with tumors known to be positive for DDR&#xD;
        (deoxyribonucleic acid damage repair) defects (such as ATM (ataxia-telangiectasia mutated)&#xD;
        deleterious mutation or low ATM expression) can be included.&#xD;
&#xD;
        Part A.1 - single-agent dose escalation part with alternative dosing schedule&#xD;
&#xD;
        - Patients with histologically confirmed solid tumors or NHL known to be positive for ATM&#xD;
        loss and/or ATM deleterious mutations will be included.&#xD;
&#xD;
        Part B - single-agent expansion part:&#xD;
&#xD;
          -  Patients with DDR deficiency biomarker-positive advanced solid tumors of the following&#xD;
             histologies: i) CRPC (castration-resistant prostate cancer); ii) HER2-negative BC that&#xD;
             is hormone-receptor positive (estrogen-receptor positive, progesterone-receptor&#xD;
             positive, or both) or TNBC (triple negative BC); iii) CRC (colorectal cancer), and iv)&#xD;
             gynecological tumors (ovarian, primary peritoneal, and fallopian tube cancers,&#xD;
             endometrial cancer, or cervical cancer).&#xD;
&#xD;
          -  The biomarker status of patients in Part B will be evaluated before general screening&#xD;
             and only patients with the presence of the putative biomarkers of DDR deficiency will&#xD;
             be recruited into general screening.&#xD;
&#xD;
          -  Patients with histologically confirmed advanced cancer, regardless of the cancer type,&#xD;
             or NHL and loss of ATM protein by IHC.&#xD;
&#xD;
        The following inclusion criteria apply to ALL (dose-escalation and expansion) patients:&#xD;
&#xD;
          -  Patients with tumors resistant or refractory to standard treatment and in which, in&#xD;
             the opinion of the investigator, experimental treatment with BAY1895344 may be of&#xD;
             benefit, Furthermore, no standard therapy would confer clinical benefit to the&#xD;
             patient.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.&#xD;
&#xD;
          -  Patients must have adequate bone marrow function as assessed by the following&#xD;
             laboratory tests to be conducted within 7 (+2) days before the first dose of study&#xD;
             drug. Note that the below values are to be independent of red blood cell transfusions&#xD;
             or granulocytes colony-stimulating factor (G-CSF) (i.e., no red blood cell or&#xD;
             platelets transfusion within 28 days prior to the screening complete blood count (CBC)&#xD;
             result, or administration of G-CSF is to occur within 14 days prior to the CBC&#xD;
             result):&#xD;
&#xD;
               1. Hemoglobin ≥ 9 g/dL; patients with chronic erythropoietin treatment consistent&#xD;
                  with institutional guidelines can be included.&#xD;
&#xD;
               2. Absolute neutrophil count (ANC) ≥ 1.5X10^9/L (≥ 1500/mm^3)&#xD;
&#xD;
               3. Platelet count ≥ 100X10^9/L (≥100,000/mm^3)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to the study drugs or excipients of the preparations or any&#xD;
             agent given in association with this study&#xD;
&#xD;
          -  History of cardiac disease: congestive heart failure New York Heart Association (NYHA)&#xD;
             class &gt;II, unstable angina (angina symptoms at rest), new-onset angina (within the&#xD;
             past 6 months before study entry), myocardial infarction within the past 6 months&#xD;
             before study entry, or cardiac arrhythmias requiring anti-arrhythmic therapy (beta&#xD;
             blockers, calcium channel blockers, and digoxin are permitted)&#xD;
&#xD;
          -  Moderate or severe hepatic impairment, i.e. Child-Pugh class B or C&#xD;
&#xD;
          -  Patients with known human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Patients who have an active hepatitis B virus (HBV) or hepatitis C virus (HCV)&#xD;
             infection requiring treatment. Patients with chronic HBV or HCV infection are eligible&#xD;
             at the investigator's discretion provided that the disease is stable and sufficiently&#xD;
             controlled under treatment.&#xD;
&#xD;
          -  Infections of CTCAE(Common Terminology Criteria for Adverse Events Version) Grade 2&#xD;
             not responding to therapy or active clinically serious infections of CTCAE Grade &gt;2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114-2696</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US Oncology</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jefferson Medical College</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology- San Antonio Northeast</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairfax-Northern Virginia Hematology/Oncology, PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OHRI - The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUQ-Hopital Hotel-Dieu de Quebec</name>
      <address>
        <city>Quebec</city>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shizuoka Cancer Center</name>
      <address>
        <city>Sunto</city>
        <state>Shizuoka</state>
        <zip>411-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <state>Sankt Gallen</state>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Institute of Southern Switzerland</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cantonal Universitaire de Genève</name>
      <address>
        <city>Genève</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velindre Hospital</name>
      <address>
        <city>Cardiff</city>
        <state>South Glamorgan</state>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHS Trust (Surrey)</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <state>Tyne And Wear</state>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>China</country>
    <country>Japan</country>
    <country>Singapore</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
    <country>Germany</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 14, 2017</study_first_submitted>
  <study_first_submitted_qc>June 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2017</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>First in human</keyword>
  <keyword>Solid tumors</keyword>
  <keyword>Lymphomas</keyword>
  <keyword>Dose escalation</keyword>
  <keyword>Dose expansion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA &quot;Principles for responsible clinical trial data sharing&quot;. This pertains to scope, timepoint and process of data access.&#xD;
As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.&#xD;
Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

